Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256657 | 0.88 | KMO (0.40) | HDAC8SLC6A2HTR2AHTR2CKMO | |
| SCHEMBL13428 | 0.83 | HDAC8 (0.48) | HDAC8SLC6A2HTR2AHTR2CMCL1 | |
| SCHEMBL30551304 | 0.83 | HDAC8 (0.48) | HDAC8SLC6A2HTR2AHTR2CMCL1 | |
| SCHEMBL14910172 | 0.78 | HDAC8 (0.44) | HDAC8SLC6A2HTR2AHTR2CMCL1 | |
| SCHEMBL31444672 | 0.77 | HDAC8 (0.43) | HDAC8SLC6A2HTR2AHTR2CSMN1; SMN2 | |
| SCHEMBL23886616 | 0.77 | HDAC8 (0.48) | HDAC8SLC6A2HTR2AHTR2CMCL1 | |
| Hydrochloric Acid SCHEMBL8035361 | 0.76 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL14250555 | 0.75 | HDAC8 (0.42) | HDAC8HTR2AHTR2CMCL1 | |
| SCHEMBL31039261 | 0.72 | EZH2 (0.32) | — | |
| SCHEMBL447125 | 0.71 | HTR2A (0.39) | HDAC8SLC6A2HTR2AHTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | HDAC8 67/4885SLC6A2 3736/4885HTR2A 4741/4885 |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | HDAC8 67/4885SLC6A2 3736/4885HTR2A 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.